EGFR mutations were originally reported to affect the clinical outcomes of ICI treatment in TKI naïve, PD-L1-positive, and EGFR-mutant patients with advanced non-small-cell lung cancer (22). The gene discussed is CD274; the disease is non-small cell lung carcinoma.